Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men

INTRODUCTION: Oral HIV Pre‐Exposure Prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC) is highly effective. Transgender women (TGW) have increased HIV risk, but have been underrepresented in trials. For TGW on oestrogens for gender‐affirming hormone treatment (GAHT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Int AIDS Soc
Main Authors: Shieh, Eugenie, Marzinke, Mark A, Fuchs, Edward J, Hamlin, Allyson, Bakshi, Rahul, Aung, Wutyi, Breakey, Jennifer, Poteat, Tonia, Brown, Todd, Bumpus, Namandjé N, Hendrix, Craig W
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6832671/
https://ncbi.nlm.nih.gov/pubmed/31692269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jia2.25405
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados